Abstract
Objectives The objective of this study is to compare two groups of women requiring termination of pregnancy from the gestational age of 85 days. All women will receive Mifepristone during their first visit to the out-patient ward. One group of women will receive Misoprostol to administer the first dose (vaginally) at home and 2 hours later they will be admitted to the in-patient ward. They will be informed to present earlier if they start bleeding or experience pain corresponding to more than normal menstrual cramping.
The other group will receive the first dose of Misoprostol (vaginally) when admitted in the in-patient ward (usually in the morning) according to current practice.
Primary objective To investigate the proportion of women who are successfully treated as day-care patients (day-care being defined as 9 hours from time of admission).
Design The study will be a randomized, controlled, multi-centred open label trial with women recruited from four hospitals in Sweden.
Competing Interest Statement
KGD reports honoraria for ad hoc lectures or participation on advisory boards from Bayer AG, Organon/MSD, Gedeon Richter, Mithra, Natural Cycles, MedinCell, Ferring, Norgene, Exelgyn, Exeltis, Cirqle, RemovAid, and Obseva. HK-K reports honoraria for lectures, participation in courses, or acting as principal investigator in trials from Abbvie, Actavis, Bayer, Gedeon Richter Exeltis, Nordic Pharma, Natural Cycles, Mithra, Teva, Merck, Organon, Ferring, Consilient Health, Evolan, Natural Cycles, Pharmiva, Dynamic Code, Ellen, Estercare, Pharmiva, Gedea, Gesynta, Essity, Preglife, and Takeda. All other authors declare no competing interests.
Clinical Protocols
https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000964-27
Funding Statement
This study was funded by grants from Regional funds Vastragotaland ALFGBG3050 and ALFGBG-966228), the Hjalmar Svensson Fund (HJSV2021003) Gothenburg Society of Medicine (974195) Region Stockholm (LS 2018-1257 and RS 2019-1054), the Swedish Research Council (2021-01042) and Region Stockholm and Karolinska Institutet ALF (FoUI-954072).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Telephone: + 46 8517 72128, Telefax no.: +46 8517-74314, E-mail: kristina.gemzell{at}ki.se, Telephone: +46-707149360, E-mail: johanna.rydelius{at}vgregion.se
Protocol Code number: WP2018
Sponsor: Kristina Gemzell Danielsson
Coordinating investigator:
2. Collaborating centres Clinics of Obstetrics and Gynaecology at: The Department of Gynecology and reproductive Medicine at Östra sjukhuset, Sahlgrenska University Hospital, Diagnosvägen 15, SE-416 85 Gothenburg, Sweden, PI: Johanna Rydelius, Helena Hognert Tel. +46 707 149360 e-mails; Johanna.rydelius{at}vgregion.se, Helena.hognert{at}vgregion.se, The Department of Obstetrics and Gynaecology, Karolinska University Hospital, Stockholm: PI Kristina Gemzell-Danielsson, Study coordinator Anette Daberius, Research midwife, WHO-centre, C1:05, Karolinska University Hospital, SE-171 76 Stockholm, Sweden Tel. +46 8 517- 72128 e-mails; Kristina.gemzell{at}ki.se, Anette.daberius{at}ki.se, The Department of Obstetrics/Gynaecology, Stockholm South General Hospital (Södersjukhuset), Stockholm: PI Cecilia Berger, co-investigator Joanna Romell, Sjukhusbacken 10, SE-118 83 Stockholm, Sweden Tel. +46 8 616 2750 e-mail; cecilia.berger{at}sll.se, The Department of Obstetrics and Gynaecology at Danderyd Hospital: PI Helena Kopp Kallner Danderyd Hospital, 182 88 Stockholm
Data Availability
All data produced in the present study are available upon reasonable request to the authors
1. Abbreviations
- GA
- gestational age
- GW
- gestational week
- TOP
- termination of pregnancy
- VAS
- visual analogue scale
- CONSORT
- Consolidated Standards of Reporting Trials
- TENS
- transcutaneous electrical nerve stimulation
- PCB
- paracervical block
- IUD
- intra-uterine device
- CRF
- case record form
- AE
- adverse event
- LPLV
- last patient last visit
- DSMB
- Data and Safety Monitoring Board
- PUL
- Swedish: personuppgiftslagen; personal records act
- ICH-GCP
- International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use – Guideline for Good Clinical Practice
